secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115724
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates
--------------------------------------------------------------------------------

- Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.
- Phase 1a dose escalation of NXP800 ongoing; Phase 1b expansion expected to start Q1 2023.
- IND-enabling studies for NXP900 ongoing; IND or equivalent submission expected Q1 2023.
- Positive preclinical data for NXP800 in ARID1a-mutated gastric cancer model.
- Cash runway into H2 2024; formed Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/0001104659-22-115724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/tm2229896d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer